Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jan 23;12:773–783. doi: 10.2147/OTT.S191239

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Sun et al. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

Cytotoxicity of fenofibrate, paclitaxel, TRAIL, ABT-737, and doxorubicin in human breast cancer cells.

Notes: (A) Fenofibrate inhibited human breast cancer cell growth in vitro. The cancer cells were incubated in the presence of various concentrations of fenofibrate for 24 and 48 hours. Cell viability was determined by the MTT assay. Each point represents the mean of the data of three independent experiments; bars represent SD; *P<0.05 vs control; **P<0.01 vs control. (B–E) Paclitaxel, TRAIL, ABT-737, and doxorubicin suppressed human breast cancer cell growth in vitro. The cancer cells were incubated in the presence of various concentrations of fenofibrate for 24 hours. Cell viability was determined by the MTT assay. Each point represents the mean of the data of three independent experiments; bars represent SD; *P<0.05 vs control; **P<0.01 vs control.

Abbreviations: DOX, doxorubicin; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand.

Cytotoxicity of fenofibrate, paclitaxel, TRAIL, ABT-737, and doxorubicin in human breast cancer cells.

Notes: (A) Fenofibrate inhibited human breast cancer cell growth in vitro. The cancer cells were incubated in the presence of various concentrations of fenofibrate for 24 and 48 hours. Cell viability was determined by the MTT assay. Each point represents the mean of the data of three independent experiments; bars represent SD; *P<0.05 vs control; **P<0.01 vs control. (B–E) Paclitaxel, TRAIL, ABT-737, and doxorubicin suppressed human breast cancer cell growth in vitro. The cancer cells were incubated in the presence of various concentrations of fenofibrate for 24 hours. Cell viability was determined by the MTT assay. Each point represents the mean of the data of three independent experiments; bars represent SD; *P<0.05 vs control; **P<0.01 vs control.

Abbreviations: DOX, doxorubicin; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand.